Cabergoline in Metastatic Breast Cancer
Cabergoline in Metastatic Breast Cancer
This study is currently recruiting participants. Verified September 2013 by Northwestern University Sponsor: Northwestern University Collaborator: Lynn Sage Foundation Information provided by (Responsible Party): Northwestern University ClinicalTrials.gov Identifier: NCT01730729 First received: November 15, 2012 Last updated: September 17, 2013 Last verified: September 2013 History of Changes
http://www.clinicaltrials.gov/ct2/ht...e/triangle.gif Purpose Prolactin is a hormone produced in the pituitary gland. Previous studies have revealed that elevated levels of the hormone prolactin might be associated with an increased risk of breast cancer. Cabergoline has been shown to lower prolactin levels in the blood. The purpose of this study is to evaluate the effectiveness of cabergoline in treating metastatic breast cancer disease in those who test positive for the prolactin receptor. |
All times are GMT -7. The time now is 09:42 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021